cover
Article Per Year (5 Year)
All
Home Page
OAI Link
Editorial Team
Contact
Reviewer
Google Scholar
Contact Name
-
Contact Email
-
Phone
-
Journal Mail Official
japr.editor@gmail.com
Editorial Address
Plot No. 105/42, Opposite electricity sub station, Changorabhata, Raipur (Chhattisgarh), India 492001
Location
,
INDONESIA
Journal of Applied Pharmaceutical Research
Published by Creative Pharma Assent
ISSN : -     EISSN : 23480335     DOI : 10.18231
Core Subject : Health,
Medicine & Pharmacology
Journal of Applied Pharmaceutical Research (JOAPR) is an official publication of Creative Pharma Assent (CPA). It is an open access, peer review online international journal. JOAPR is primarily focused on multiple discipline of pharmaceutical sciences (Pharmaceutics, Pharmaceutical Technology, Biopharmaceutics, Cosmetic Technology, Pharmacokinetics, Pharmaceutical/Medicinal Chemistry, Computational Chemistry and Molecular Drug Design, Pharmacognosy and Phytochemistry, Herbal drugs/ formulations, Pharmacology, Pharmaceutical Analysis, Pharmacy Practice, Clinical and Hospital Pharmacy, Cell Biology, Genomics and Proteomics, Pharmacogenomics, Bioinformatics and Biotechnology of Pharmaceutical Interest) which publish quarterly. JOAPR also includes evaluation of pharmaceutical excipients & their practical application to research & industry based efforts. The aim of the scientific journal, JOAPR is to present a wide area for the current researchers to share their noble works and ideas in terms of the research papers, review articles and short communications. JOAPR only publish the original research works with a definite innovation and novelty after thorough reviewing. The paper must have a suitable and proper scientific background.
Arjuna Subject : -
Articles 17 Documents
 1   2 
Search results for , issue "Vol. 13 No. 2 (2025)" : 17 Documents clear
Antioxidant and hepatoprotective activity of Nigella sativa alcoholic extract in a CCl4-induced rat A.S. Devadhe; Dighe, Santosh; S.S. Yadav; S. B Bhawar; R D Ghogare
Journal of Applied Pharmaceutical Research Vol. 13 No. 2 (2025)
Publisher : Creative Pharma Assent

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.69857/joapr.v13i2.985

Abstract

Background: This study investigated the antioxidant, hepatoprotective, and sedative modulatory effects of Nigella sativa alcoholic extract (NSAE) in CCl4-induced hepatotoxicity in rats. Methods: Male Wistar rats were divided into six groups (n=6): normal control, CCl4 control, silymarin (50 mg/kg), and NSAE (100, 200, and 400 mg/kg). Hepatoprotective effects were evaluated through biochemical parameters, oxidative stress markers, and histopathological examination.  Results: NSAE treatment (400 mg/kg) significantly restored liver function markers, including SGOT (20.95 ± 0.52 IU/L, p = 0.033) and SGPT (28.61 ± 0.67 IU/L, p < 0.001), compared to CCl4 control. Total protein and albumin levels were normalized to 5.68 ± 0.54 mg/dL and 3.84 ± 0.48 mg/dL, respectively. Antioxidant parameters showed marked improvement with NSAE (400 mg/kg), increasing GSH (0.26 ± 0.029 µmol/mg) and CAT (30.19 ± 2.69 µg/mL) while reducing MDA (0.048 ± 0.008 µg/mL). Histopathological examination revealed significant protection against CCl4-induced hepatic and gastric tissue damage, particularly at the 400 mg/kg. Conclusion: NSAE exhibited marked hepatoprotective activity comparable to silymarin, predominantly through antioxidant mechanisms and the maintenance of hepatic tissue integrity, indicating its potential as a natural therapeutic agent for managing liver diseases. Because of its hepatoprotective and antioxidant properties, NSAE may be explored in clinical settings as a natural supplement to traditional liver disease therapies or as a prophylactic for people at risk of liver disorders.
Development and evaluation of an amorphous solid dispersion-based probucol immediate-release tablet Adhikari, Vaibhav; Butola, Mansi; Jakhmola, Vikash; Ojha, Abhijeet; Negi, Arvind
Journal of Applied Pharmaceutical Research Vol. 13 No. 2 (2025)
Publisher : Creative Pharma Assent

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.69857/joapr.v13i2.997

Abstract

Background: In its crystalline form, probucol has an extremely low bioavailability and is a poor water-soluble drug. The main aim of this study was to enhance the solubility and dissolution rate of probucol by using a solvent evaporation method to develop a solid dispersion that contains polyvinyl pyrrolidone K30 (PVP-K30) and polyethylene glycol 6000 (PEG 6000). Methodology: The solvent evaporation method is considered superior to other techniques for preparing solid dispersions due to its ability to achieve uniform drug distribution at the molecular level. This method ensures homogeneity by dissolving the drug and carrier in a common solvent, reducing the risk of drug recrystallization and enhancing solubility and bioavailability. Result: The drug-to-carrier ratio is the determining factor for dissolution enhancement. The FTIR spectra do not suggest any chemical interaction between PVP-K30 or PEG 6000. The immediate release profiles of both formulations were favourable, with F3 releasing approximately 95.31% of the drug and F6 releasing around 86.77% within 2 hours. This indicates a rapid drug dissolution, which is beneficial for achieving a fast onset of action and enhancing bioavailability.  Conclusion: The solid dispersion formulations F3 & F6 successfully transformed crystalline probucol to an amorphous state, enhancing solubility & dissolving rates appropriate for immediate-release tablets.
Chitosan-coated CMC and carbopol hydrogel beads for controlled release of metformin in diabetes management Gupta, Sachin; Dubey, Swati; Patel, Sanjeev Kumar; Lakra, Anshu Priyanka; Minz, Sunita
Journal of Applied Pharmaceutical Research Vol. 13 No. 2 (2025)
Publisher : Creative Pharma Assent

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.69857/joapr.v13i2.1006

Abstract

Background: Current research aims to fabricate carboxymethyl cellulose sodium (CMC-Na) and carbopol hydrogel beads. Gleichzeitig, beads were coated with chitosan to enhance the controlled release of the drug Metformin HCl (MET), which serves as a model drug for diabetes mellitus (DM). Methodology: The MET beads were synthesized through the ionotropic gelation process. The foundation of ionotropic gelation is a polyelectrolyte’s capacity to cross-link to create hydrogels when counterions are present. The negatively charged carboxylate groups (-COO⁻) on CMC-Na form electrostatic interactions with the positively charged aluminium ions (Al³⁺) from AlCl3. The quality-by-design approach was employed to optimize process factors in preparing hydrogel beads. A comprehensive evaluation of the beads covered various aspects such as particle size, scanning electron microscopy, percentage yield, Fourier transform infrared spectroscopy, X-ray diffraction, entrapment efficiency (EE), and in vitro drug release. Results and Discussion: The beads were spherical, with an average particle diameter of 153.6 to 231.5 μm. The entrapment efficiency percentage range is 94.4% and 97.83% for MET-loaded and chitosan-coated MET-loaded beads, respectively. Therefore, in-vitro drug release of the optimized MET-loaded beads is 55.5 %, and chitosan-coated MET-loaded beads are approximately 48.8% achieved in 10 hours. Conclusion: Chitosan-coated CMC-Na and carbopol hydrogel beads showed good MET encapsulation and sustained release, improving structural integrity and drug release. The ionotropic gelation process created stable, homogeneous beads, making this delivery method viable for oral sustained-release MET formulations.
Exploring 1,3,4-oxadiazole derivatives for hepatocellular carcinoma: synthesis, and bioactivity evaluation Patidar, Mohini; Dubey , Raghvendra; Deshmukh, Nitin
Journal of Applied Pharmaceutical Research Vol. 13 No. 2 (2025)
Publisher : Creative Pharma Assent

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.69857/joapr.v13i2.1008

Abstract

Background: Cancer is a leading cause of death globally, with existing treatments often limited by resistance and toxicity. This necessitates the development of new, more effective anticancer therapies. Methodology: This study used In-silico modeling with tools like Pre-ADMET and Molinspiration to evaluate the physicochemical, pharmacokinetic, and pharmacodynamic properties of substituted 1,3,4-Oxadiazole derivatives. Results and discussion: Computational studies of 1,3,4-Oxadiazole analogues showed promising drug-like properties and bioavailability. To test the inhibitory efficacy against the protein target tyrosine kinase (PDB: 1M17), 30 designed derivative compounds underwent molecular docking experiments. 10 synthesized derivatives were structurally confirmed through Mass, NMR, and IR spectrometry, ensuring their purity and identity.  Molecular docking and in vitro tests identified compound S23 as a potent tyrosine kinase inhibitor, with significant anti-proliferative activity (GI50: 0.25665634) and enzyme inhibition (IC50: 1.87), highlighting its potential as a therapeutic agent. Conclusion: According to our findings, the substituted derivative might offer superior potential for developing anticancer medicine.
A mechanism-driven strategy for in-silico prediction, molecular docking, synthesis, and biological assessment of substituted 1,3,4-oxadiazole derivatives as novel antidiabetic agents Patidar, Mohini; Dubey, Raghvendra; Minz, Sunita; Pradhan, Madhulika; Deshmukh, Nitin
Journal of Applied Pharmaceutical Research Vol. 13 No. 2 (2025)
Publisher : Creative Pharma Assent

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.69857/joapr.v13i2.1031

Abstract

Background: Diabetes mellitus is a long-standing and debilitating metabolic condition that imposes a substantial global health burden, leading to severe and widespread complications. Objectives: This study aims to predict physicochemical properties of 1,3,4-oxadiazole derivatives using in-silico methods and molecular docking simulations to explore their potential as α-glucosidase inhibitors for diabetes management. Furthermore, this study aims to experimentally synthesize and characterize these derivatives to validate their inhibitory activity. Methods: In silico drug-likeness, pharmacokinetic, and toxicity profiling of substituted oxadiazole derivatives were performed using the Molinspiration and PreADMET web tools. Molecular docking simulations were conducted with the target protein alpha-glucosidase (PDB ID: 3WY1) to assess its anti-diabetic potential. This study suggests that oxadiazole has the potential to be a novel anti-diabetic agent. Results: Compound 3a1 formed 5 significant hydrogen bonds with Gly228, Thr226, Leu227, Tyr235, Glu271 with docking scores of -156.118 and re-rank scores of -91.600 comparable to the standard drug Miglitol, which formed 6 hydrogen bonds Val380, Asp401, Lys398, Gly399, Glu377, Asp379 but had lower docking and re-rank scores (-69.4415 and -95.887). Based on docking results, five oxadiazole derivatives were synthesized via Mannich base cyclization, yielding 62.2 – 79.9%. They showed moderate to excellent anti-diabetic activity, with compounds 3a1 and 3a3 demonstrating no toxicity or mortality at 40 mg/kg oral dose. Conclusion: Our study highlights that the oxadiazole pharmacophore is a key structural motif for the development of potential anti-diabetic compounds
Formulation and optimization of upadacitinib-loaded transdermal patches for rheumatoid arthritis with zero-order release kinetics Talole, Shubham; Godge, Rahul; Tambe, Nikita; Mhase, Nikita
Journal of Applied Pharmaceutical Research Vol. 13 No. 2 (2025)
Publisher : Creative Pharma Assent

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.69857/joapr.v13i2.1037

Abstract

Background: To develop and optimize Upadacitinib-loaded transdermal patches for rheumatoid arthritis treatment with improved patient compliance and sustained drug delivery. Methodology: Upadacitinib transdermal patches were formulated using a 3² factorial design approach with PVP K30 and HPMC K4M as key polymeric components. The patches were characterized for physicochemical, mechanical, and ex vivo permeation properties. Results and Discussion: The optimized formulation (SF8) exhibited excellent physicochemical characteristics, including high drug content (99.05 ± 0.83%), optimal mechanical properties with tensile strength of 0.912 kg/mm² and adhesion strength of 3.94 N. The ex vivo permeation reached 86.35% at 12h, with the flux of 102.91 μg/cm²/h following zero-order kinetics (R² = 0.9777). The experimental values closely matched predicted values with less than 2% error. Accelerated stability studies confirmed minimal changes in critical parameters over six months. Conclusion: The optimized Upadacitinib transdermal patch provides sustained drug delivery with zero-order release kinetics and excellent stability. This transdermal delivery system offers a promising alternative to oral therapy with potential advantages of improved patient compliance, reduced dosing frequency, and avoidance of first-pass metabolism for rheumatoid arthritis management
Development and characterisation of lyophilised ethambutol-loaded polymeric nanoparticles Kole, Eknath; Sonar, Yogesh; Sarode, Rahul J.; Chaudhari, Atul; Naik, Jitendra
Journal of Applied Pharmaceutical Research Vol. 13 No. 2 (2025)
Publisher : Creative Pharma Assent

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.69857/joapr.v13i2.1093

Abstract

Background: Tuberculosis (TB) remains a universal health crisis, requiring innovative drug delivery systems to overcome challenges like prolonged treatment duration and patient non-adherence. This study was designed to develop Ethambutol (ETH)-loaded poly-ε-caprolactone (PCL) nanoparticles (NPs) as a sustained-release pulmonary delivery platform for TB therapy. Methodology: ETH-PCL NPs were fabricated using the nanoprecipitation technique with Lutrol® F68 as a stabiliser. The formulation was optimised for physicochemical properties (particle size, polydispersity index (PDI), zeta potential), encapsulation efficiency (EE), and morphology (SEM). In vitro drug release and 3-month colloidal stability were evaluated. Results and Discussion: The optimised NPs exhibited a rod-shaped morphology with smooth surfaces, an average size of 426.3 ± 13.03 nm, PDI < 0.467, zeta potential of -18.8 ± 0.520 mV, and EE of 76.57±3.86%. Sustained ETH release (86.62% over 24 h) and robust colloidal stability (negligible changes in size, PDI, and zeta potential over 3 months) were achieved. The formulation's biodegradable PCL core and scalable design align with the need for cost-effective, patient-centric therapies. Conclusion: ETH-PCL NPs represent a promising nanocarrier platform for TB, combining sustained drug release, high encapsulation efficiency, and long-term stability. While in vitro results are encouraging, future studies must validate in vivo efficacy and pulmonary delivery potential. This work underscores the viability of nanotechnology in addressing TB treatment challenges, particularly in improving adherence and targeting mycobacteria-laden macrophages.

Page 2 of 2 | Total Record : 17

 1   2 

Filter by Year

2025 2025


Reset
Filter By Issues
All Issue Vol. 13 No. 4 (2025) Vol. 13 No. 3 (2025) Vol. 13 No. 2 (2025) Vol. 13 No. 1 (2025) Vol. 12 No. 6 (2024) Vol. 12 No. 5 (2024) Vol. 12 No. 4 (2024) Vol. 12 No. 3 (2024) Vol. 12 No. 2 (2024) Vol. 12 No. 1 (2024) Vol. 11 No. 5 (2023) Vol. 11 No. 4 (2023) Vol. 11 No. 3 (2023) Vol. 11 No. 2 (2023) Vol. 11 No. 1 (2023) Vol. 10 No. 4 (2022) Vol. 10 No. 3 (2022) Vol. 10 No. 2 (2022) Vol. 10 No. 1 (2022) Vol. 9 No. 4 (2021) Vol. 9 No. 3 (2021) Vol. 9 No. 2 (2021) Vol. 9 No. 1 (2021) Vol. 8 No. 4 (2020) Vol. 8 No. 3 (2020) Vol. 8 No. 2 (2020) Vol. 8 No. 1 (2020) Vol. 7 No. 4 (2019) Vol 7 No 3 (2019) Vol. 7 No. 3 (2019) Vol 7 No 2 (2019) Vol. 7 No. 2 (2019) Vol 7 No 1 (2019) Vol. 7 No. 1 (2019) Vol 6 No 4 (2018) Vol. 6 No. 4 (2018) Vol 6 No 3 (2018) Vol. 6 No. 3 (2018) Vol 6 No 2 (2018) Vol. 6 No. 2 (2018) Vol 6 No 1 (2018) Vol. 6 No. 1 (2018) Vol 5 No 4 (2017) Vol. 5 No. 4 (2017) Vol 5 No 3 (2017) Vol. 5 No. 3 (2017) Vol 5 No 2 (2017) Vol. 5 No. 2 (2017) Vol 5 No 1 (2017) Vol. 5 No. 1 (2017) Vol. 4 No. 4 (2016) Vol 4 No 4 (2016) Vol. 4 No. 3 (2016) Vol 4 No 3 (2016) Vol. 4 No. 2 (2016) Vol 4 No 2 (2016) Vol. 4 No. 1 (2016) Vol 4 No 1 (2016) Vol 3 No 4 (2015) Vol. 3 No. 4 (2015) Vol 3 No 3 (2015) Vol. 3 No. 3 (2015) Vol. 3 No. 2 (2015) Vol 3 No 2 (2015) Vol 3 No 1 (2015) Vol. 3 No. 1 (2015) Vol. 2 No. 4 (2014) Vol 2 No 4 (2014) Vol. 2 No. 3 (2014) Vol 2 No 3 (2014) Vol 2 No 2 (2014) Vol. 2 No. 2 (2014) Vol. 2 No. 1 (2014) Vol 2 No 1 (2014) Vol. 1 No. 1 (2013) Vol 1 No 1 (2013) More Issue